Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) have earned a consensus rating of “Hold” from the seven research firms that are currently covering the firm. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $135.00.
IDXX has been the subject of a number of analyst reports. Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, April 5th. Canaccord Genuity set a $125.00 price target on IDEXX Laboratories and gave the company a “buy” rating in a research report on Monday, January 23rd. Finally, Feltl & Co. downgraded IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, February 3rd.
In other news, Director Daniel M. Junius sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Wednesday, February 8th. The stock was sold at an average price of $141.75, for a total value of $425,250.00. Following the transaction, the director now owns 5,495 shares in the company, valued at $778,916.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Brian P. Mckeon sold 9,924 shares of the firm’s stock in a transaction dated Wednesday, February 8th. The stock was sold at an average price of $141.64, for a total value of $1,405,635.36. Following the completion of the sale, the vice president now directly owns 45,235 shares in the company, valued at $6,407,085.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 84,174 shares of company stock worth $11,955,273. Company insiders own 2.79% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. acquired a new stake in IDEXX Laboratories during the third quarter valued at about $1,021,000. Bank of Montreal Can boosted its stake in IDEXX Laboratories by 52.8% in the third quarter. Bank of Montreal Can now owns 19,188 shares of the company’s stock valued at $2,163,000 after buying an additional 6,627 shares during the last quarter. First Quadrant L P CA acquired a new stake in IDEXX Laboratories during the third quarter valued at about $2,375,000. GW&K Investment Management LLC boosted its stake in IDEXX Laboratories by 25.3% in the third quarter. GW&K Investment Management LLC now owns 134,219 shares of the company’s stock valued at $15,131,000 after buying an additional 27,068 shares during the last quarter. Finally, CWM LLC boosted its stake in IDEXX Laboratories by 941.2% in the third quarter. CWM LLC now owns 1,770 shares of the company’s stock valued at $200,000 after buying an additional 1,600 shares during the last quarter. 91.42% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This report was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2017/04/21/idexx-laboratories-inc-idxx-receives-consensus-rating-of-hold-from-brokerages-updated-updated.html.
Shares of IDEXX Laboratories (NASDAQ:IDXX) traded down 0.25% during midday trading on Monday, reaching $159.12. The company’s stock had a trading volume of 451,334 shares. The company has a 50-day moving average price of $152.76 and a 200-day moving average price of $128.66. IDEXX Laboratories has a 12 month low of $80.33 and a 12 month high of $159.92. The firm has a market cap of $14.00 billion, a price-to-earnings ratio of 65.21 and a beta of 0.48.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, February 2nd. The company reported $0.58 EPS for the quarter, topping the Zacks’ consensus estimate of $0.51 by $0.07. IDEXX Laboratories had a negative return on equity of 671.57% and a net margin of 12.51%. The firm earned $443 million during the quarter, compared to analyst estimates of $436.07 million. During the same period last year, the company earned $0.48 earnings per share. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. Equities analysts expect that IDEXX Laboratories will post $2.94 earnings per share for the current year.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
What are top analysts saying about IDEXX Laboratories Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for IDEXX Laboratories Inc. and related companies.